March 2026 in “The Journal of Dermatology” Ritlecitinib is cost-effective for severe alopecia areata in Japan.
64 citations
,
June 2020 in “PLoS ONE” Red light boosts beneficial compounds in Eclipta alba cultures.
June 2021 in “Research Square (Research Square)” Adverse events in lung cancer treatments increase fear, anxiety, and depression, with newer therapies causing fewer side effects.
68 citations
,
January 2014 in “Dermatology research and practice” Skin side effects from cancer drugs targeting EGFR can affect treatment adherence but can be managed with antibiotics like tetracycline.
1 citations
,
March 2019 in “Journal of Interdisciplinary Medicine” A patient with multiple sclerosis developed skin reactions after Daclizumab treatment, requiring more data on the drug's effects.
26 citations
,
October 2018 in “Cancer Management and Research” High DKK1 levels predict worse survival in head and neck cancer.
September 2023 in “Journal of the American Academy of Dermatology” Ixekizumab is safe for long-term use with low rates of major heart-related events.
May 2025 in “Cellular Oncology” Blocking both P-cadherin and c-Met can effectively stop head and neck cancer growth.
January 2016 in “Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München)” FDG PET/CT can improve cancer treatment plans in dogs.
6 citations
,
May 2013 in “Journal of Clinical Oncology” Combining Ficlatuzumab and Gefitinib can cause severe hair loss.